FDA Approves Cemiplimab as Adjuvant Treatment for Cutaneous . . . Cemiplimab's approval is supported by findings from the C-POST clinical trial The FDA approved cemiplimab-rwlc (Libtayo; Regeneron Pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) who are at a high risk of recurrence following surgery and radiation
FDA approves Regeneron’s Libtayo for cutaneous . . . - MSN The Food and Drug Administration approved cemiplimab-rwlc, or Libtayo, from Regeneron (REGN) Pharmaceuticals for the adjuvant treatment of adults with cutaneous squamous cell carcinoma at high
LIBTAYO® (cemiplimab-rwlc) | Official HCP Website LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk CSCC See Important Safety full Prescribing Information
Specialty Guideline Management Libtayo - info. caremark. com Brand Name Generic Name Libtayo cemiplimab-rwlc Indications The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy FDA-Approved Indications